|By Jonathan Roseland||Connect|
This Japanese-developed Racetam is one of the latest nootropics to be inspired by Piracetam.
In 2005, the Mitsubishi Tanabe Pharmaceutical Corporation registered Coluracetam and began studying its potential usefulness as an Alzheimer’s disease treatment. Although the results of the company’s clinical trials were not what they had hoped for, there were still some potential benefits associated with this substance. Therefore, BrainCells Inc. took over the licensing for Coluracetam, and they conducted testing that showcased this racetam’s potential as a way to help people who are combating anxiety and major depressive disorder.